A common problem in Phase II clinical trials is the comparison of dose response curves corresponding to different treatment groups. If the effect of the dose level is described by parametric regression models and the treatments differ in the administration frequency (but not in the sort of drug) a reasonable assumption is that the regression models for the different treatments share common parameters. This paper develops optimal design theory for the comparison of different regression models with common parameters. We derive upper bounds on the number of support points of admissible designs, and explicit expressions for D-optimal designs are derived for frequently used dose response models with a common location parameter. If the lo...
In the pharmaceutical industry, dose selection is a critical step in early phase II clinical trials....
A recently described design method for one-parameter biomedical models such as limiting or serial di...
Dose finding studies often compare several doses of a new compound with a marketed standard treatme...
A common problem in Phase II clinical trials is the comparison of dose response curves corresponding...
estimating the underlying dose-response curve for a restricted or unrestricted dose range with respe...
In dose response studies, the dose range is often restricted due to concerns over drug toxicity and/...
In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/...
We consider the optimal design problem for a comparison of two regression curves, which is used to ...
Consider the problem of estimating a dose with a certain response rate. Many multistage dose-finding...
In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/...
One of the most complex tasks during the clinical development of a new drug is to find a correct dos...
Random effects models are widely used in population pharmacokinetics and dose finding studies. In ...
We consider a dose-finding trial in phase IIB of drug development. For choosing an appropriate desi...
D-optimality is a commonly used criterion to evaluate a design with respect to parameter estimation....
The pharmaceutical industry now recognises the importance of the newly defined discipline of pharmac...
In the pharmaceutical industry, dose selection is a critical step in early phase II clinical trials....
A recently described design method for one-parameter biomedical models such as limiting or serial di...
Dose finding studies often compare several doses of a new compound with a marketed standard treatme...
A common problem in Phase II clinical trials is the comparison of dose response curves corresponding...
estimating the underlying dose-response curve for a restricted or unrestricted dose range with respe...
In dose response studies, the dose range is often restricted due to concerns over drug toxicity and/...
In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/...
We consider the optimal design problem for a comparison of two regression curves, which is used to ...
Consider the problem of estimating a dose with a certain response rate. Many multistage dose-finding...
In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/...
One of the most complex tasks during the clinical development of a new drug is to find a correct dos...
Random effects models are widely used in population pharmacokinetics and dose finding studies. In ...
We consider a dose-finding trial in phase IIB of drug development. For choosing an appropriate desi...
D-optimality is a commonly used criterion to evaluate a design with respect to parameter estimation....
The pharmaceutical industry now recognises the importance of the newly defined discipline of pharmac...
In the pharmaceutical industry, dose selection is a critical step in early phase II clinical trials....
A recently described design method for one-parameter biomedical models such as limiting or serial di...
Dose finding studies often compare several doses of a new compound with a marketed standard treatme...